跳至主要内容
临床试验/NCT01494441
NCT01494441已完成不适用

A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

Medtronic Spinal and Biologics0 个研究点目标入组 27 人开始时间: 1999年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
27
主要终点
Pain/Disability Status

研究概览

简要总结

The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:
  • instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
  • osteophyte formation;
  • decreased disc height;
  • thickening of ligamentous tissue;
  • disc degeneration or herniation; and/or
  • facet joint degeneration.
  • Has preoperative Oswestry score >
  • Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
  • Requires fusion of a single level disc space from L1 to S
  • Is at least 18 years of age, inclusive, at the time of surgery.
  • Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
  • If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
  • Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

排除标准

  • Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
  • Had previous spinal fusion surgical procedure at the involved level.
  • Require spinal fusion at more than one lumbar level.
  • Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
  • Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  • Has presence of active malignancy.
  • Has overt or active bacterial infection, either local or systemic.
  • Is grossly obese, i.e., weight > 40% over ideal for their age and height.
  • Has fever ( temperature >101°F oral) at the time of surgery.
  • Has a documented titanium alloy allergy or intolerance.
  • Is mentally incompetent. If questionable, obtain psychiatric consult.
  • Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
  • Is a prisoner.
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
  • Is a tobacco user at the time of surgery.
  • Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).
  • Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
  • Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
  • Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
  • Has received any previous exposure to any/all BMPs of either human or animal extraction.
  • Has a history of severe allergy (anaphylaxis).
  • Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).

结局指标

主要结局

Pain/Disability Status

时间窗: 24 month

The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score \>= 15

Fusion

时间窗: 24 month

Fusion is defined as: 1. Evidence of bridging trabecular bone. 2. No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs; 3. Absence of radiolucent lines completely through the fusion mass.

次要结局

  • Pain Status (back pain, leg pain)(24 month)
  • Overall Success(24 month)
  • Hip (Donor Site) Pain(24 month)
  • General Health Status (SF-36)(24 month)
  • Neurological Status Success(24 month)
  • Patient Satisfaction(24 month)
  • Patient Global Perceived Effect(24 month)

研究者

发起方
Medtronic Spinal and Biologics
申办方类型
Industry
责任方
Sponsor

相似试验